Journal article · 2017 · Open access

Regulatory considerations on endpoints in ovarian cancer drug development

Sanjeeve Balasubramaniam, Geoffrey S. Kim, Amy E. McKee, Richard Pazdur

Cancer, 123(14), 2604–2608 · Published 12 May 2017 · DOI 10.1002/cncr.30652

Open PDFView at the publisherCite this paper

In brief

“Regulatory considerations on endpoints in ovarian cancer drug development” is a 2017 journal article by Sanjeeve Balasubramaniam and 3 co-authors, published in Cancer. OpenAlex counts 6 citations as of 22 November 2026. It is open access: the full text is free to read at Cancer.

Citations
6
Most cited in
2017 (2)
Field-weighted impact
0.61
References
13
Authors
4

Abstract

Ovarian cancer remains a disease entity that is responsible for considerable morbidity and mortality among women worldwide. Modern drug research pipelines and accelerated drug development timelines applied to other disease entities have begun to make an impact on treatment options for patients with advanced ovarian cancer, as exemplified by the recent accelerated approval of 2 agents for this disease as the forerunners of a growing number of registrational trials. Regulatory flexibility for this serious and life-threatening condition spurs the consideration of intermediate endpoints for regulatory trial design, including potential applications in the development of newer therapeutic classes such as targeted therapies and immunotherapies for patients with advanced ovarian cancer. Cancer 2017;123:2604-8. © 2017 American Cancer Society.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Balasubramaniam, S., Kim, G. S., McKee, A. E., & Pazdur, R. (2017). Regulatory considerations on endpoints in ovarian cancer drug development. Cancer, 123(14), 2604–2608. https://doi.org/10.1002/cncr.30652

MLA 9

Balasubramaniam, Sanjeeve, et al. “Regulatory considerations on endpoints in ovarian cancer drug development.” Cancer, vol. 123, no. 14, 2017, pp. 2604–2608. https://doi.org/10.1002/cncr.30652.

Chicago

Balasubramaniam, Sanjeeve, Geoffrey S. Kim, Amy E. McKee, and Richard Pazdur. 2017. “Regulatory considerations on endpoints in ovarian cancer drug development.” Cancer 123 (14): 2604–2608. https://doi.org/10.1002/cncr.30652.

Harvard

Balasubramaniam, S. et al. (2017) ‘Regulatory considerations on endpoints in ovarian cancer drug development’, Cancer, 123(14), pp. 2604–2608. doi:10.1002/cncr.30652.

IEEE

S. Balasubramaniam, G. S. Kim, A. E. McKee, and R. Pazdur, “Regulatory considerations on endpoints in ovarian cancer drug development,” Cancer, vol. 123, no. 14, pp. 2604–2608, 2017, doi: 10.1002/cncr.30652.

BibTeX

@article{balasubramaniam2017regulatory,
  title     = {{Regulatory considerations on endpoints in ovarian cancer drug development}},
  author    = {Balasubramaniam, Sanjeeve and Kim, Geoffrey S. and McKee, Amy E. and Pazdur, Richard},
  journal   = {Cancer},
  year      = {2017},
  volume    = {123},
  number    = {14},
  pages     = {2604--2608},
  doi       = {10.1002/cncr.30652},
  url       = {https://doi.org/10.1002/cncr.30652}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201722
201822
202011
202611

Its field-weighted citation impact is 0.61: it has been cited 0.61 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment

  • ovarian cancer
  • drug development
  • regulatory endpoints
  • intermediate endpoints
  • accelerated approval
  • targeted therapy
  • immunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Balasubramaniam, S., Kim, G. S., McKee, A. E., & Pazdur, R. (2017). Regulatory considerations on endpoints in ovarian cancer drug development. Cancer, 123(14), 2604–2608. https://doi.org/10.1002/cncr.30652

How many times has this paper been cited?

6 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Sanjeeve Balasubramaniam, Geoffrey S. Kim, Amy E. McKee, Richard Pazdur.

What is the DOI of this paper?

10.1002/cncr.30652, permanently at https://doi.org/10.1002/cncr.30652. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.